0001628280-25-051167 Sample Contracts
EMPLOYMENT AGREEMENTEmployment Agreement • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations • New York
Endo, Inc. Malvern, PA 19355 July 29, 2025 Scott Hirsch Hirsch.Scott@endo.com Re: Noncompetition and Consulting Agreement Dear Scott:Noncompetition and Consulting Agreement • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
Reference is hereby made to that certain letter between you and Endo, Inc. (the “Company”) dated as of August 26, 2024, as amended by that certain letter between you and the Company dated as of January 6, 2025, and that certain letter between you and the Company dated as of March 13, 2025 (the “Transition Letter” and, collectively, your “Employment Agreement”). In partial consideration for the compensation and benefits provided under the Transition Letter, you hereby agree to the obligations set forth in this letter. The effectiveness of the obligations set forth in this letter (this “Agreement”) is contingent upon the consummation of the transactions (the “Combination”) contemplated by that certain Transaction Agreement, dated March 13, 2025, between Mallinckrodt plc, the Company and Salvare Merger Sub LLC, and if the Combination is not consummated, the rights and obligations set forth in this Agreement shall be void ab inito and of no force or effect. This Agreement shall modify the
FOURTH SUPPLEMENTAL INDENTURESupplemental Indenture • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
WHEREAS, the Issuer and the Guarantors have heretofore executed and delivered to the Trustee an indenture, dated as of April 23, 2024, by and among the parties thereto (as amended, supplemented or otherwise modified from time to time, the “Indenture”), providing for the issuance of 8.500% Senior Secured Notes due 2031 (the “Notes”);
SECOND SUPPLEMENTAL INDENTURESupplemental Indenture • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
WHEREAS, the Issuer and the Guarantors have heretofore executed and delivered to the Trustee an indenture, dated as of April 23, 2024, by and among the parties thereto (as amended, supplemented or otherwise modified from time to time, the “Indenture”), providing for the issuance of 8.500% Senior Secured Notes due 2031 (the “Notes”);
First Lien Intercreditor Agreement JoinderFirst Lien Intercreditor Agreement Joinder • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
SUPPLEMENT NO. 2 dated as of August 1, 2025 (this “Supplement”), to the FIRST LIEN INTERCREDITOR AGREEMENT dated as of April 23, 2024 (the “First Lien Intercreditor Agreement”), among Endo LP (f/k/a Endo, Inc.) (“Holdings”), Endo Finance Holdings, Inc. (“Borrower”), the other Grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the Credit Agreement Secured Parties (in such capacity and together with its successors in such capacity, the “Bank Collateral Agent”), and Computershare Trust Company, National Association, as collateral agent for the Indenture Secured Parties (in such capacity and together with its successors in such capacity, the “Notes Collateral Agent”), and each Additional Agent from time to time party thereto.
First Lien Intercreditor Agreement JoinderFirst Lien Intercreditor Agreement Joinder • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
SUPPLEMENT NO. 3 dated as of September 26, 2025 (this “Supplement”), to the FIRST LIEN INTERCREDITOR AGREEMENT dated as of April 23, 2024 (the “First Lien Intercreditor Agreement”), among Endo LP (f/k/a Endo, Inc.) (“Holdings”), Endo Finance Holdings LP (f/k/a Endo Finance Holdings, Inc.) (“Borrower”), the other Grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the Credit Agreement Secured Parties (in such capacity and together with its successors in such capacity, the “Bank Collateral Agent”), and Computershare Trust Company, National Association, as collateral agent for the Indenture Secured Parties (in such capacity and together with its successors in such capacity, the “Notes Collateral Agent”), and each Additional Agent from time to time party thereto.
First Lien Intercreditor Agreement JoinderFirst Lien Intercreditor Agreement Joinder • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
SUPPLEMENT NO. 1 dated as of June 30, 2025 (this “Supplement”), to the FIRST LIEN INTERCREDITOR AGREEMENT dated as of April 23, 2024 (the “First Lien Intercreditor Agreement”), among Endo, Inc. (“Holdings”), Endo Finance Holdings, Inc. (“Borrower”), the other Grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the Credit Agreement Secured Parties (in such capacity and together with its successors in such capacity, the “Bank Collateral Agent”), and Computershare Trust Company, National Association, as collateral agent for the Indenture Secured Parties (in such capacity and together with its successors in such capacity, the “Notes Collateral Agent”), and each Additional Agent from time to time party thereto.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective duly authorized officers as of the day and year first above written. ENDO, INC., as Parent By: /s/ Deanna Voss Name: Deanna Voss...Credit Agreement • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURESupplemental Indenture • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations
WHEREAS, the Issuer and the Guarantors have heretofore executed and delivered to the Trustee an indenture, dated as of April 23, 2024, by and among the parties thereto (as amended, supplemented or otherwise modified from time to time, the “Indenture”), providing for the issuance of 8.500% Senior Secured Notes due 2031 (the “Notes”);
ENDO USA, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 10th, 2025 • Mallinckrodt PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT (this “Agreement”) is hereby effective as of __________ (the “Effective Date”), by and between Endo USA, Inc. (the “Company”), a wholly-owned subsidiary of Endo, Inc. (“Endo”), and __________ (“Executive”) (hereinafter collectively referred to as “the parties”).